Community Counts: Exploring Transcription Regulation & Immunotherapy for ES-SCLC: Tweetorial #1

 

 

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

PROGRAM OVERVIEW

Accounting for only 13% of all lung cancer cases, small cell lung cancer (SCLC) is pathologically and molecularly distinct from non-small cell lung cancer (NSCLC) and is far more aggressive. Most patients (~75%) are diagnosed with metastatic disease and although SCLC initially responds well to 1st-line chemotherapy, relapse within 2 to 4 months is common. There are currently only 2 approved treatments for SCLC after relapse – one of which was approved in 2020 and is largely unfamiliar to clinicians. This new agent, lurbinectedin, operates on a completely different mechanism of action by inhibiting oncogenic transcription. A few immune checkpoint inhibitors (ICIs) have also been approved for SCLC in the 1st- and 3rd-lines of treatment. This activity will familiarize clinicians with how these entities work to improve outcomes in SCLC

FACULTY

Narjust Duma, MD
Associate Director of Cancer Care Equity
Thoracic Oncologist
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Member of the Faculty
Harvard Medical School
Boston, Massachusetts

 

Jacob M. Sands, MD
Thoracic Oncologist
Dana-Farber Cancer Institute
Instructor of Medicine
Harvard Medical School
Boston, Massachusetts

 

Release date: November 23, 2021
Expiration date: November 23, 2022
Estimated time to complete activity: 30 minutes

 

TARGET AUDIENCE

This educational activity has been designed to meet the needs of oncologists, pathologists, histologists, pulmonologists, and fellows in the aforementioned specialties.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Compare efficacy and safety data for new and emerging treatments for second-line extensive-stage-SCLC (ES-SCLC), as well for immunotherapies approved in subsequent lines
  • Develop a plan of action for selecting appropriate treatment options for ES-SCLC patients who evidence disease progression during or after first-line chemotherapy
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of November 23, 2021 through November 23, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.

MEDIA

Internet

ACCREDITATION

Physician Continuing Education

 

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this other activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Narjust Duma, MD
Consulting Fees (eg. advisory boards): AstraZeneca, BI Oncology, Bristol-Myers Squibb, Janssen, Pfizer
Speakers’ Bureaus: Neogenomics

 Jacob M. Sands, MD
Consulting Fees: AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Lilly, Medtronic, Pharma Mar, Takeda

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest